A phase II study of oral weekly 4-demethoxydaunorubicin in advanced breast cancer

D B Smith, A Howell

Research output: Contribution to journalArticlepeer-review


Thirty-eight patients with advanced breast cancer were treated with oral 4-demethoxydaunorubicin in a continuous weekly schedule at a dose of 15 mg/m2/week. Subjective toxicity consisted of mild nausea (grade 1) in 52% with more severe GI side effects (grade 2) in 15%. Three patients developed grade 1 alopecia and there were no episodes of cardiac failure. Significant neutropenia (grade 2/3) only occurred in patients with marrow involvement or widespread bone disease. There was one CR and 5 PRs, an overall response rate of 15.7% (95% confidence limits 6-31%). In addition 6 patients had disease stabilization for at least 6 months. Fourteen patients progressing on 4-demethoxydaunorubicin have received adriamycin 60 mg/m2 21 days. There have been 5 PRs in this group indicating possible non-cross-resistance between these two agents.

Original languageEnglish
Pages (from-to)391-394
Number of pages4
JournalEuropean Journal of Cancer and Clinical Oncology
Issue number4
Publication statusPublished - Apr 1987


  • Adult
  • Aged
  • Antibiotics, Antineoplastic
  • Breast Neoplasms
  • Daunorubicin
  • Doxorubicin
  • Drug Evaluation
  • Female
  • Humans
  • Idarubicin
  • Middle Aged
  • Journal Article
  • Research Support, Non-U.S. Gov't


Dive into the research topics of 'A phase II study of oral weekly 4-demethoxydaunorubicin in advanced breast cancer'. Together they form a unique fingerprint.

Cite this